StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research note published on Thursday morning. The brokerage issued a sell rating on the stock.
Ayala Pharmaceuticals Stock Performance
Shares of ADXS opened at $0.56 on Thursday. Ayala Pharmaceuticals has a fifty-two week low of $0.50 and a fifty-two week high of $1.95. The company has a market capitalization of $5.97 million, a PE ratio of -0.07 and a beta of 1.63. The stock has a fifty day moving average of $0.67 and a two-hundred day moving average of $0.72.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last released its earnings results on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
See Also
- Five stocks we like better than Ayala Pharmaceuticals
- How to Evaluate a Stock Before Buying
- MarketBeat Week in Review – 4/29 – 5/3
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is MarketRank™? How to Use it
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
